Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -63.3%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $9M | $11M | $38M | $29M | $673M | $1.7B | $391M | $510M | $790M | $1.3B |
| Enterprise Value | $-7097574 | $-2096557 | $8M | $29M | $12M | $643M | $1.7B | $360M | $504M | $786M | $1.3B |
| P/E Ratio → | -0.39 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.95 | 2.25 | 1.91 | 12.87 | 17.22 | 723.25 | 1651.98 | 519.87 | 291.88 | 233.60 | 198.42 |
| P/B Ratio | 0.28 | 0.72 | 0.72 | 1.34 | 0.83 | 10.61 | 30.20 | 6.50 | 10.14 | 11.38 | 14.87 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.54 | 1.48 | 9.76 | 7.04 | 691.36 | 1609.88 | 477.67 | 288.56 | 232.58 | 197.92 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -6.3% | -6.3% | 57.3% | 50.0% | 45.7% | 17.5% | 44.8% | 55.6% | 16.9% | 15.9% | 13.8% |
| Operating Margin | -364.2% | -364.2% | -337.2% | -745.5% | -1608.4% | -3328.3% | -2386.0% | -2810.9% | -1144.2% | -649.1% | -322.5% |
| Net Profit Margin | -220.2% | -220.2% | -295.6% | -800.8% | -1590.3% | -2988.5% | -2247.5% | -2405.3% | -1188.2% | -616.3% | -299.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.3% | -63.3% | -75.8% | -75.2% | -54.2% | -46.2% | -39.9% | -32.8% | -34.7% | -26.6% | -20.5% |
| ROA | -28.3% | -28.3% | -36.2% | -44.5% | -40.2% | -37.5% | -32.6% | -27.9% | -30.5% | -24.0% | -18.8% |
| ROIC | -154.5% | -154.5% | -88.6% | -89.7% | -78.5% | -99.1% | -89.6% | -43.5% | -27.1% | -21.9% | -17.8% |
| ROCE | -74.3% | -74.3% | -57.6% | -47.0% | -44.9% | -47.0% | -38.8% | -35.6% | -31.7% | -26.8% | -21.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.87 | 0.40 | 0.34 | 0.04 | 0.04 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.90 | -0.16 | -0.32 | -0.49 | -0.47 | -0.77 | -0.53 | -0.12 | -0.05 | -0.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -7.05 | -7.05 | -118.91 | -127.67 | -122.78 | -74.73 | -96.42 | -53.08 | -147.39 | -161.45 | -136.06 |
Net cash position: cash ($13M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.38 | 4.38 | 1.15 | 4.96 | 6.71 | 8.27 | 5.36 | 8.53 | 10.22 | 15.61 | 17.13 |
| Quick Ratio | 4.32 | 4.32 | 1.06 | 4.95 | 6.61 | 8.25 | 5.36 | 8.53 | 10.22 | 15.61 | 17.13 |
| Cash Ratio | 3.77 | 3.77 | 0.82 | 4.47 | 6.29 | 7.83 | 4.98 | 8.16 | 10.03 | 15.38 | 16.86 |
| Asset Turnover | — | 0.19 | 0.14 | 0.06 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 | 0.07 |
| Inventory Turnover | 19.50 | 19.50 | 1.31 | 19.61 | 1.61 | 8.34 | — | — | — | — | — |
| Days Sales Outstanding | — | 178.28 | 97.32 | 98.41 | 174.98 | 460.76 | 760.88 | 586.52 | 155.86 | 87.77 | 65.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $8M | $6M | $5M | $4M | $41M | $37M | $26M | $26M | $26M | $25M |
Liquidity and dilution risk
Based on reported figures, Evogene trades at a price-to-sales ratio of 0.87, which appears to reflect a significant conglomerate discount when compared to the broader biotech sector, suggesting the market is heavily discounting the potential for future milestone-driven revenue growth across its diverse subsidiary portfolio.
The current valuation multiple suggests that investors are assigning minimal value to the company's proprietary computational biology platform, likely due to the persistent lack of commercial scale. This pricing implies a market skepticism regarding the company's ability to successfully monetize its R&D pipeline through licensing or royalty agreements in the near term.
As reported in financial statements, Evogene's ROIC has remained consistently negative, reaching -7.8% in 2026Q1, which highlights a fundamental inability to generate returns on invested capital that exceed the company's cost of funding, a trend that has persisted throughout the last ten quarters.
The persistent negative ROIC indicates that the capital deployed into the company's various subsidiaries is not currently yielding productive economic value. This trend warrants further investigation into whether the company's hub-and-spoke model is inherently inefficient or if it is simply in a prolonged phase of capital-intensive development.
According to recent SEC filings, the company's cash conversion cycle has exhibited extreme volatility, swinging from 17 days in 2026Q1 to over 1,200 days in previous periods, reflecting the highly unpredictable nature of milestone-based revenue collections and inventory management across its disparate business segments.
This extreme variability in the cash conversion cycle suggests that the company lacks a stable operational rhythm, making it difficult to forecast liquidity needs. Investors should monitor whether the recent compression in the cycle represents a sustainable improvement in operational efficiency or merely a temporary anomaly in revenue timing.
Based on reported figures, the current ratio has declined to 2.79 in 2026Q1 from higher levels in previous periods, indicating that while the company maintains a nominal liquidity buffer, the rapid depletion of cash reserves leaves little room for operational error or unforeseen market disruptions.
The company's liquidity position appears increasingly fragile as it continues to burn through cash to support its R&D initiatives. Given the lack of recurring revenue, the current liquidity profile suggests that the company may face significant pressure to secure additional financing in the near future.
The most commonly misapplied ratio for Evogene is the price-to-sales multiple, which obscures the company's true economic reality by failing to distinguish between sustainable commercial revenue and volatile, one-time milestone payments that do not reflect long-term business viability.
Using P/S ratios to value a platform-based R&D company like Evogene is misleading because it ignores the underlying value of the intellectual property and the potential for future royalty streams. Analysts should instead focus on the sum-of-the-parts valuation of individual subsidiaries, adjusting for the non-controlling interests that often dilute the parent company's claim on future earnings.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EVGN stock.
Evogene Ltd.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Evogene Ltd.'s return on equity (ROE) is -63.3%. The historical average is -36.6%.
Based on historical data, Evogene Ltd. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Evogene Ltd. has -6.3% gross margin and -364.2% operating margin.